Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CCR2 Antibody - BSA Free, Novus Biologicals™

Rabbit Polyclonal Antibody has been used in 6 publications
Supplier: Novus Biologicals NBP148337SS
Description
CCR2 Polyclonal specifically detects CCR2 in Human, Rat, Bovine, Feline samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
CCR2 | |
Polyclonal | |
Unconjugated | |
PBS and 30% Glycerol with 0.1% Sodium Azide | |
C-C chemokine receptor type 2, C-C CKR-2, CC-CKR-2CKR2B, CCR-2, CCR2A, CCR2B, CD192, CD192 antigen, chemokine (C-C motif) receptor 2, CKR2, CKR2A, CMKBR2MGC111760, FLJ78302, MCP-1 receptor, MCP-1-RMGC103828, MGC168006, Monocyte chemoattractant protein 1 receptor, monocyte chemotactic protein 1 receptor | |
Rabbit | |
Affinity Purified | |
RUO | |
Primary | |
Human. Reactivity with Rat reported by varified customer. The immunogen sequence similarity with other species: Rhesus monkey and several other primate species (100%), Mouse (69%). | |
Store at -20C. Avoid freeze-thaw cycles. |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
1 mg/mL | |
Western Blot 2 ug/ml, Flow Cytometry 5 ug/ml, Immunohistochemistry 5 ug/ml, Immunocytochemistry/Immunofluorescence 1:50, Immunohistochemistry-Paraffin 5 ug/ml | |
P41597 | |
CCR2 | |
Synthetic peptide made to an N-terminal portion of the human CCR2 protein (within residues 20-100). [Swiss-Prot# P00338] | |
0.025 mL | |
Chemokines and Cytokines, Cytokine Research, GPCR, Immunology, Innate Immunity, Signal Transduction | |
729230 | |
Human, Rat, Bovine, Feline | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction